Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWR
Apel Daniel Joseph sold 13,095 Arrowhead Pharmaceuticals, Inc. shares (Form 4)
Traded Apr 22, 2026 · Filed Apr 24, 2026
On Apr 22, 2026, Apel Daniel Joseph (Chief Financial Officer) sold 13,095 Arrowhead Pharmaceuticals, Inc. shares at an average US$71.35 for US$934K under a trading plan, leaving 162,905 shares. Filed Apr 24, 2026 (Form 4).
- Sold
- 13,095 shares
- Price
- US$71.35 average (US$70.11 to US$71.92)
- Value
- US$934K
- Holding after
- 162,905 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Financial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Common Stock | Sale | 3,208 | US$70.11 | 172,792 | Direct |
| Apr 22, 2026 | Common Stock | Sale | 1,157 | US$70.45 | 171,635 | Direct |
| Apr 22, 2026 | Common Stock | Sale | 8,730 | US$71.92 | 162,905 | Direct |
Source
Related
- Arrowhead Pharmaceuticals, Inc.
- Apel Daniel Joseph
- Arrowhead Pharmaceuticals, Inc. shareholders
- Form 4 · Olukotun Adeoye Y · Aug 20, 2026
- Form 4 · Perry Michael S · Aug 20, 2026
- Schedule 13G/A · Avoro Capital Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Vanguard Portfolio Management LLC · Jul 31, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 27, 2026